Plexxikon Inc.

Medarex Inc.

Renovis, Inc.

Opna Immuno-oncology Sa

Guoxian Wu

Prabha N Ibrahim

Wayne Spevak

Jiazhong Zhang

Chao Zhang

Songyuan Shi

Ying Zhang

Jack Lin

Marika Nespi

Dean R Artis

Todd Ewing

Phuongly Pham

John Buell

Howard P Ng

Hanna Cho

Oliver L Saunders

Ryan Bremer

Danny P C McGee

Katrina Chan

Jeffrey Yung Wu

Hongyao Zhu

Zhi-Hong Li

Valeri Martichonok

Zuojun Guo

Sanjeev Gangwar

Michael G Kelly

Yong-Liang Zhu

Irina Astafieva

Jimmie L Moore

John Kincaid

Aaron Edward Albers

Satyanarayana Janagani

Hannah Powers

David J King

Thomas Jay Lobl

Zhihong Li

Gideon Bollag

Zhi-Liang Wei

Sharon Elaine Boyd

James Tsai

Jack Walleshauser

Yunfeng Fang

Shenghua Shi

Klaus-Peter Hirth

Rebecca Zuckerman

Gaston G Habets

Ken Dong

David Lonergan

Jeffrey Wu

Brian L West

Matthew Duncton

Geoffrey T Yarranton

Shumeye Mamo

Hiroaki Inagaki

Carl J Kaub

Clarence R Hurt

Ravindra B Upasani

Jianming Tsai

Samuel J Gillette

Yoshihisa Suzuki

Elizabeth A Burton

Yong Zhou

Jianhua He, Legal Representative

Oliver L Saunder

Garson Tsang

Yoshisa Suzuki

Kiran Sahasrabudhe

Danny Pc McGee

Yongil Jin

Danny P Mcgee

Geoffrey Thomas Yarranton

Aaron Albers

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds and methods for EP300 or CBP modulation and indications therefor

Disclosed are compounds of Formula (I) and (Ia): 

Compounds and methods for IDO and TDO modulation, and indications therefor

Compounds and methods for CDK8 modulation and indications therefor

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof

Disclosed are compounds of Formula I(a): 

Disclosed are compounds having a compound of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, compositions thereof, and uses thereof.

Compounds and methods for kinase modulation

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R, R, R, each R, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R, R, Q, Q, and Q, are described in this disclosure, compositions thereof, and methods and uses thereof.

Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z, Z, and Zare as described herein, compositions thereof, and uses thereof.

Growing community of inventors

Foster City, CA, United States of America

Guoxian Wu